Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality

During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.